anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare the titled composition having high safety and excellent safety and feeling to the skin, and useful for the remedy of liver-spots, freckles, dark skin, pimples, etc., by using a specific dicarboxylic acid ester as an active component. CONSTITUTION:The objetive composition contains 0.1-40wt% 7-13C dicarboxylic acid ester of formula (n is 5-11; R1 is ethyl or isopropyl; R2 is ethyl, isopropyl or H), e.g. monoethyl pimelate, as an active component. Although it is already known that the dicaboxylic acid has a pharmacological activity to cure stains, freckles, dark skin, pimples, etc., it is diffucult to form the dicarboxylic acid in an administrable form. The dicarboxylic acid ester used in the present composition has high stability in the composition, can be reconstituted to dicarboxylic acid by the enzymatic activity in the skin when applied to skin, and exhibits remarkable remedying effect to the above symptoms of the skin. Furthermore, the troubles such as skin irritation, etc. can also be eliminated.
PURPOSE:To obtain a peculiar adsorbing body having an adsorptivity for hepatitis virus, by covalently bonding an antibody for the antigen of a hepatitis virus to a chitin fiber. CONSTITUTION:An antibody for the antigen of a hepatitis virus (hereinafter mentioned as an HV antibody) is covalently bonded to a chitin fiber to obtain a peculiar adsorbing body having an adsorptivity for hepatitis virus. As a manipulation method for bonding the HV antibody to the chitin fiber, a method for immersing the chitin fiber in an HV antibody solution or a solution mixture of the HV antibody and a condensing reagent is mainly used. This adsorbing body is high in capacity for peculiarly adsorbing the hepatitis virus and has no danger of causing elimination of other effective substances in blood, serum or an injection. In addition, because it is fibrous, handling is easy as well as adsorptivity per unit wt. is large and sufficient mechanical strength and stability are shown in performing adsorbing manipulation.
Of the total number of patients in clinical studies of RELISTOR tablets, a total of 136 patients (10%) were aged 65 years and older, while 23 (2%) were aged 75 and older. In clinical studies of RELISTOR tablets, no overall differences in effectiveness were observed. Adverse reactions were similar; however, there was a higher incidence of diarrhea in elderly patients.

Of the total number of patients in clinical studies of RELISTOR injection, a total of 226 (28%) were aged 65 years and older, while 108 (13%) were aged 75 years and older. In clinical studies of RELISTOR injection, no overall differences in safety or effectiveness were observed between elderly patients and younger patients.

Based on pharmacokinetic data, and safety and efficacy data from controlled clinical trials, no dosage adjustment based on age is recommended. Monitor elderly patients for adverse reactions.
Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE was comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled "Self-Care Skills for the Person with Diabetes", created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSE messages could not be customized. There was no interactive content for the DSE arm other than a once monthly message asking whether the messages had been helpful.
AIMS: Given the possible radiation damage and inaccuracy of radiological investigations, particularly in children, ultrasound and superb microvascular imaging (SMI) may offer alternative methods of evaluating new bone formation when limb lengthening is undertaken in paediatric patients. The aim of this study was to assess the use of ultrasound combined with SMI in monitoring new bone formation during limb lengthening in children.
METHODS: In this retrospective cohort study, ultrasound and radiograph examinations were performed every two weeks in 30 paediatric patients undergoing limb lengthening. Ultrasound was used to monitor new bone formation. The number of vertical vessels and the blood flow resistance index were compared with those from plain radiographs.
RESULTS: We categorized the new bone formation into three stages: stage I (early lengthening), in which there was no obvious callus formation on radiographs and ultrasound; stage II (lengthening), in which radiographs showed low-density callus formation with uneven distribution and three sub-stages could be identified on ultrasound: in Ia punctate callus was visible; in IIb there was linear callus formation which was not yet connected and in IIc there was continuous linear callus. In stage III (healing), the bone ends had united, the periosteum was intact, and the callus had disappeared, as confirmed on radiographs, indicating healed bone. A progressive increase in the number of vertical vessels was noted in the early stages, peaking during stages IIb and IIc, followed by a gradual decline (p < 0.001). Delayed healing involved patients with a prolonged stage IIa or those who regressed to stage IIa from stages IIb or IIc during lengthening.
CONCLUSION: We found that the formation of new bone in paediatric patients undergoing limb lengthening could be reliably evaluated using ultrasound when combined with the radiological findings. This combination enabled an improved assessment of the prognosis, and adjustments to the lengthening protocol. While SMI offered additional insights into angiogenesis within the new bone, its role primarily contributed to the understanding of the microvascular environment rather than directly informing adjustments of treatment.
Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
The prevalence of chronic obstructive pulmonary disease (COPD) is 11.7% around the world in 2010, and it is expected to rise over the next 30 years. COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lung, characterized by chronic cough, dyspnea, and sputum production. Studies have found evidences of inspiratory muscle weakness in patients with COPD which include a reduction in maximal inspiratory pressure (PImax), a shift toward oxidative type I fibers and atrophy in all types of fibers in diaphragm muscle. The shift of diaphragm muscle fiber toward oxidative type I fibers might result from endurance training-like effect that served to counteract the negative effects of elevated oxidative stress and systemic inflammation in patients with COPD.

Inspiratory muscle training (IMT) is commonly applied to patients with COPD during pulmonary rehabilitation, but its clinical benefits remain inconclusive. Some studies showed that IMT improves breathing pattern, dyspnea and the strength and endurance of diaphragm, while others showed that IMT could not improve inspiratory muscle strength and functional exercise capacity either applied alone or in addition to pulmonary rehabilitation in patients with COPD. Evidence from animal study showed that overloading the diaphragm during resistive breathing might induce acute diaphragm injury. Increases oxidative stress and systemic inflammation, and exacerbating the apoptosis of the diaphragm fibers may also occur during IMT in patients with COPD, which leads to the progression of diaphragm muscle fibers atrophy. In human studies, the intensity used for IMT ranged from 10% to 70% of PImax, and the training effect showed no clear dose-response pattern. The optimal intensity that would induce positive physiological effect without eliciting overloading injury remains unclear. In healthy adults, the accessory muscles, such as sternocleidomastoid (SCM), scalenes, and intercostals muscle, would be recruited to assist ventilation with increasing ventilatory demand. Thus the activation of accessory muscles could be an indicator for training overload. However, the activation pattern of accessory muscle has not been studied in patients with COPD during IMT. Whether the commonly prescribed intensity for IMT would lead to excessive activation of diaphragm, and more accessory muscle recruitment in patients with COPD remains to be determined. Therefore, the purpose of this study is to exam diaphragm and SCM muscle activation using surface electromyography during loaded inspiratory muscle tests with 30% and 50% of PImax intensity.
Low back pain (LBP) is a leading cause of disability that results in significant health and socioeconomic problems. Most of the LBP is non-specific and altered motor control is one of the possible causes. Motor control exercise (MCE) thus has been recently developed as a non-operative intervention for LBP. Recently, a series of lumbar movement control (LMC) tests have been advocated to evaluate impaired motor control of lumbar. To perform a coordinated movement pattern, normal proprioception (part of neural system) is thought to be essential. Poor proprioception related to delayed muscle response and altered motor control which possibly leading to deficits in postural control and balance in LBP population. Study showed standing balance was related to higher physical activity (PA) which has been promoted in all adults and proper amount is at least 150 to 300 minutes of moderate-intensity aerobic physical activity; or at least 75 to 150 minutes of vigorous-intensity aerobic physical activity per week for substantial health benefits. As we know, there is no specific research about the relationship among PA, LMC and standing balance. Therefore, the purposes of the study are to investigate (1) the influence of different level of PA on LMC tests; (2) the influence of PA on standing balance; (3) the relationship of battery of LMC tests and standing balance in adults with and without LBP.

It is expected to recruit total 160 participants with and without LBP. The inclusion criteria for adults with LBP are: (1) aged from 20 to 65 years old, (2) persistent LBP for more than 3 months. For adults without LBP are: (1) aged from 20 to 65 years old, (2) no specific low back pain in the past 6 months. All the participants will fill in International PA Questionnaire (IPAQ), Short form Taiwan Version, perform proprioception test for the lumbar spine, LMC tests, timed one-leg standing balance, and Y-balance test for the lower quarter (YBT-LQ). After finishing the examination, all the data will be analyzed by mix analysis of variance (ANOVA) and Chi-square analysis. Bonferroni post-hoc tests will be used to identify the significance within each analysis. Level of statistical significance was set at p\<0.05.

Keywords: Physical activity, motor control exercise, lumbar movement control, standing balance, proprioception
Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
The invention discloses a stroke nourishing cream which comprises five traditional Chinese medicine components including lucid ganoderma, polygonum multiflorum, coix seeds, walnuts and honey, wherein the traditional Chinese medicine components are calculated according to parts by weight: 12 parts of ganoderma lucidum; 12 parts of polygonum multiflorum; 10 parts of coix seed; 10 parts of walnut; 10 parts of honey. The invention also discloses a preparation method of the stroke nourishing ointment, which comprises the steps of weighing the traditional Chinese medicines according to the weight proportion, respectively grinding the different traditional Chinese medicines into fine paste, and then uniformly mixing and stirring to prepare the ointment. The invention also discloses a using method of the stroke nourishing cream, and the using amount of the stroke nourishing cream is as follows: three times a day, each time, 100ml of water is infused with 30ml of ointment. The invention is mainly used for treating the symptoms of deficiency of liver-yin and kidney-yin and deficiency of essence and blood, and the symptoms are dizziness and headache, insomnia and dreamful sleep, palpitation and amnesia, unsmooth stool, cough and asthma and the like. Is mainly used for treating hypertension, coronary heart disease, cerebral arteriosclerosis, fatty liver and hypercholesterolemia. It is especially suitable for senile asthenia with symptoms of dyspnea, insomnia, dry stool, etc., and can be taken for a long time.
FIELD: medicine. SUBSTANCE: method involves applying radiation gamma-therapy, regional chemotherapy and surgical treatment of penis carcinoma at the first-second stage of the disease development. The total dose of radiation and gamma-radiation therapy exposure time are reduced, circular exsection of the prepuce and radical exsection of the primary tumor within the limits of healthy tissues of the penis are carried out. System-level poly-chemotherapy and regional chemotherapy based on catheterization of interior iliac artery of the patient and continuous 96 h long perfusion of antitumor agent of bleomycin through vascular catheter into regional arterial bed of the penis by means of metering apparatus are applied 4-6 weeks later after operation in combination with artificial excitation and supporting erection state during 3 min by means of negative local pressure using local decompression apparatus. 6 exposures of local decompression of patient penis are carried out daily with 2 h intervals during 4 days long continuous perfusion of bleomycin solution. 3 weeks later, repeated course of the mentioned combined chemotherapy is carried out with periodically induced artificial erection and vascular catheter installation into the interior iliac artery through femoral artery on the other side of patient body. EFFECT: enhanced effectiveness of treatment. 3 cl, 2 dwg
An udder soothing mixture preferably includes water, peppermint oil, menthol, tea tree oil, an emulsifying agent and a carrier. The peppermint oil, menthol and tea tree oil are organic active ingredients. The emulsifying agent is preferably Simulgel, but other emulsifying agents may also be used. The carrier is preferably Glycerin USP, but other carriers may also be used. The peppermint oil, menthol, tea tree oil and Glycerin USP are mixed together. The Glycerin USP absorbs the peppermint oil, menthol and tea tree oil. The Glycerin USP mixture is combined with Simulgel. Water is then added to the Simulgel mixture. The udder soothing mixture may be sprayed by a manual or automated sprayer. It is preferable to add coloring to udder soothing mixture.
The dosage of opioid analgesics like hydromorphone hydrochloride should be individualized for any given patient, since adverse events can occur at doses that may not provide complete freedom from pain.

Safe and effective administration of opioid analgesics to patients with acute or chronic pain depends upon a comprehensive assessment of the patient. The nature of the pain (severity, frequency, etiology, and pathophysiology) as well as the concurrent medical status of the patient will affect selection of the starting dosage.

In non-opioid-tolerant patients, therapy with hydromorphone is typically initiated at an oral dose of 2 to 4 mg every four hours, but elderly patients may require lower doses (see PRECAUTIONS: Geriatric Use). 

In patients receiving opioids, both the dose and duration of analgesia will vary substantially depending on the patient's opioid tolerance. The dose should be selected and adjusted so that at least 3 to 4 hours of pain relief may be achieved. In patients taking opioid analgesics, the starting dose of hydromorphone hydrochloride should be based on prior opioid usage. This should be done by converting the total daily usage of the previous opioid to an equivalent total daily dosage of oral hydromorphone hydrochloride using an equianalgesic table (see below). For opioids not in the table, first estimate the equivalent total daily usage of oral morphine, then use the table to find the equivalent total daily dosage of hydromorphone hydrochloride.

Once the total daily dosage of hydromorphone hydrochloride has been estimated, it should be divided into the desired number of doses. Since there is individual variation in response to different opioid drugs, only 1/2 to 2/3 of the estimated dose of hydromorphone hydrochloride calculated from equivalence tables should be given for the first few doses, and then increased as needed according to the patient's response.

Since the pharmacokinetics of hydromorphone are affected in hepatic and renal impairment with a consequent increase in exposure, patients with hepatic and renal impairment should be started on a lower starting dose (see CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism). 

In chronic pain, doses should be administered around-the-clock. A supplemental dose of 5 to 15% of the total daily usage may be administered every two hours on an "as-needed" basis.

Periodic reassessment after the initial dosing is always required. If pain management is not satisfactory and in the absence of significant opioid-induced adverse events, the hydromorphone dose may be increased gradually. If excessive opioid side effects are observed early in the dosing interval, the hydromorphone dose should be reduced. If this results in breakthrough pain at the end of the dosing interval, the dosing interval may need to be shortened. Dose titration should be guided more by the need for analgesia than the absolute dose of opioid employed.
Foliar diseases of maize are among the most important diseases of maize worldwide. This study focused on 4 major foliar diseases of maize: Goss's wilt, gray leaf spot, northern corn leaf blight, and southern corn leaf blight. QTL mapping for resistance to Goss's wilt was conducted in 4 disease resistance introgression line populations with Oh7B as the common recurrent parent and Ki3, NC262, NC304, and NC344 as recurrent donor parents. Mapping results for Goss's wilt resistance were combined with previous studies for gray leaf spot, northern corn leaf blight, and southern corn leaf blight resistance in the same 4 populations. We conducted (1) individual linkage mapping analysis to identify QTL specific to each disease and population; (2) Mahalanobis distance analysis to identify putative multiple disease resistance regions for each population; and 3) joint linkage mapping to identify QTL across the 4 populations for each disease. We identified 3 lines that were resistant to all 4 diseases. We mapped 13 Goss's wilt QTLs in the individual populations and an additional 6 using joint linkage mapping. All Goss's wilt QTL had small effects, confirming that resistance to Goss's wilt is highly quantitative. We report several potentially important chromosomal bins associated with multiple disease resistance including 1.02, 1.03, 3.04, 4.06, 4.08, and 9.03. Together, these findings indicate that disease QTL distribution is not random and that there are locations in the genome that confer resistance to multiple diseases. Furthermore, resistance to bacterial and fungal diseases is not entirely distinct, and we identified lines resistant to both fungi and bacteria, as well as loci that confer resistance to both bacterial and fungal diseases.
Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
1,176,244. Isomerizing Vitamin A compounds. CHAS. PFIZER & CO. Inc. 17 May, 1967 [8 Nov., 1966], No. 22987/67. Addition to 1,053,574. Heading C2V. Isomers of Vitamin A, and esters thereof, of low biological activity, namely 9 cis, 9, 13dicis, 11cis and 11, 13di-cis isomers, are converted to mixtures of increased activity, mainly Vitamin A and neo-Vitamin A, and esters thereof, by reaction with iodine and a basic amine at 0‹ to 115‹ C. in an inert solvent. The basic amine may be used as a solvent. The iodine may be removed from the reaction mixture with a reducing agent, preferably an alkali metal borohydride. The reaction with the iodine and basic amine also improves the colour, odour and stability of the products of subsequent esterification or transesterification of Vitamin A compounds. In examples, Vitamin A acetate isomers are reacted with iodine and pyridine, the iodine being reduced with sodium borohydride.
The objectives of this feasibility study are; 1) To obtain pilot data for a full-scale study and measure the distribution of parameters of the hypoxia MR (perfusion, diffusion, oxygenation, and acidosis) imaging, 2) To assess association of various hypoxia MR metrics with outcome, response to chemoradiotherapy (CRT) determined by 3 months post CRT FDG-PET/CT. 3) The metrics developed on hypoxia MRI wil be validated against F-18 FMISO-PET/CT and whole specimen IHC (immunohistochemistry). The data obtained from this pilot study will allow us to measure the effect size (difference in hypoxia MR metrics between responder and non-responder) for a larger, full-scale diagnostic study in the future, as well as to determine which hypoxia MR parameters have a strong association with desired outcome (response to CRT) in the future study.

The long-term objective of this research is to evaluate hypoxia MR phenotype that can be incorporated into treatment planning for IMRT (intensity-modulated radiotherapy), identify subregions of tumor hypoxia, and predict response to chemoradiotherapy (CRT) in newly diagnosed head and neck squamous cell carcinoma. The investigators will develop hypoxia MRI using a widely available MRI platform that allows broad patients access to novel hypoxia MRI. The investigators will evaluate the accuracy of the prediction of response to CRT using quantitative variables derived from hypoxia MR at the baseline as well as early interval changes between the baseline and 2 weeks of intra-treatment MR scans. Response to CRT will be determined by 3 months post-treatment FDG-PET/CT.